@article {BenderP07.141作者={海蒂本德和埃菲Mitsis Sano和玛丽和简马丁和珍妮花Woehr和安娜Miley-Akerstedt和斯蒂芬妮城镇和拉尔Kostakoglu和马丁Goldstein和约瑟夫Machac撒母耳铁路工人},title ={神经心理测试确定患者病理水平的β-Amyloid住大脑通过Florbetapir F18正电子发射断层扫描(P07.141)},体积={80}={7}补充数量,页面= {P07.141——P07.141} ={2013},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:确定患者神经心理测试确定的临床效用大脑β-Amyloid病理水平的生活。首页背景:新fda florbetapir F18宠物与高亲和力和特异性配体β-amyloid允许体内定量评估这一目标生物标志物的广告。设计/方法:一个案例进行了系列包括11名参与者,60 - 89岁,历史的认知功能障碍。神经心理学测试电池评估注意力,执行能力,语言、运动速度、学习和记忆是管理。临床诊断(即。遗忘MCI,广告、FTLD vascular-related痴呆或临床正常)是由神经心理学家那些盲目的宠物的发现。所有参与者接受了临床评估florbetapir PET扫描由核医学视觉得分作为病理水平的积极或消极β-amyloid聚合。结果:五个参与者被诊断出患有遗忘MCI, 4 FTLD, 2临床正常展示,没有广告或vascular-related痴呆。积极florbetapir F18 PET扫描中发现4的MCI患者;0的FTLD和那些被认为是正常的。结论:研究结果表明,神经心理测试健壮的临床实用程序确定广告的遗忘MCI患者表现出生物标志物在florbetapir F18 PET成像。这些数据强调的好处neurometrics早期识别过程,从而促进准确的诊断和通知治疗计划。披露:本德博士没有披露。Mitsis博士没有披露。 Dr. Sano has received personal compensation for activities with Aventis, Bayer, Forest, Glaxo SmithKline, Jansen, Medication, Bristol Myer Squib, OrthoMcNeil and Takeda as a consultant and advisor. Dr. Sano received compensation for serving as scientific advisor to Voyager Pharmaceutical. Dr. Martin has nothing to disclose. Dr. Woehr has nothing to disclose. Dr. Miley-Akerstedt has nothing to disclose. Dr. Towns has nothing to disclose. Dr. Kostakoglu has nothing to disclose. Dr. Goldstein has nothing to disclose. Dr. Machac has nothing to disclose. Dr. Gandy has received personal compensation for activities with Johnson \& Johnson, Pfizer Inc, Alzheimer Immunotherapy Alliance, Diagenic, Amicus, and Baxter.Thursday, March 21 2013, 2:00 pm-7:00 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/80/7_Supplement/P07.141}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }